Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Factors Associated with Risk of Recurrent Transient Global Amnesia
JAMA Neurol 77:1551-1558, Morris, K.A.,et al, 2020
Cyclic Vomiting Syndrome in Children
AJGH 2:doi:10.33552/AJGH.2020, Al-Ansari, N., 2020
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Treatment Effects and Comorbid Diseases in 58 Patients with Visual Snow
Neurol 93:e398-e403, vanDongen, R.M.,et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Abdominal Migraine
BMJ 360;k179, Angus-Leppan, H.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Migraine and Risk of Perioperative Ischemic Stroke and Hospital Readmission: Hospital Based Registry Study
BMJ 356:e6635, Timm. F.P.,et al, 2017
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Increased Risk of Bell Palsy in Patients with Migraine
Neurol 84:116-124, Peng, K.P.,et al, 2015
Acute Headache Diagnosis in Pregnant Women
Neurol 85:1024-1030, Robbins, M.S.,et al, 2015
Evidence-Based Treatments for Adults with Migraine
Pain Reser Treat 2015:DOI:10.1155/2015/629382, Gooriah, R.,et al, 2015
Transient Ischemic Attack Requiring Hospitalization of Children in the United States
Stroke 45:887-888, Adil, M.M.,et al, 2014
Chronic Migraine
BMJ 348:g141b, Schwedt, T.J., 2014
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Stroke-Like Migraine Attacks after Radiation Therapy (SMART) Syndrome is not Always Completely Reversible: A Case Series
AJNR 34:2298-2303, Black, D.F.,et al, 2013
SMART Syndrome (Stroke-Like Migraine Attacks After Radiation Therapy) in Adult and Pediatric Patients
J Child Neurol 29:336-341, Armstrong, A.E.,et al, 2013
Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults
JAMA 307:1736-1745, Jackson,J.L.,et al, 2012
Comorbidity of Migraine in Children Presenting with Epilepsy to a Tertiary Care Center
Neurol 79:468-473, Kelly, S.A.,et al, 2012
An Uncommon Cause of Intracerebral Hemorrhage in a Healthy Truck Driver
Arch Neurol 69:1500-1503, Gokhale, S.,et al, 2012
Neurological Complications of Sclerotherapy for Varicose Veins
J Vasc Surg 55:243-251, Sarvananthan, T.,et al, 2012
Clinical and MRI characteristics of acute migrainous infarction
Neurol 76:1911-1917, Wolf, M.E.,et al, 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Risk Development of Medication Overuse Headache With Nonsteroidal Anti-inflammatory Drug Therapy for Migraine A Critically Appraised Topic
The Neurologist 17:297-299, Starling, A.J.,et al, 2011
Differential Features of Carotid and Vertebral Artery Dissections
Neurol 77:1174-1181, Debette, S.,et al, 2011
OnabotulinumtoxinA Improves Quality of Life and Reduces Impact of Chronic Migraine
Neurol 77:1465-1472, Lipton, R.B.,et al, 2011
Intravenous Dihydroergotamine for Inpatient Management of Refractory Primary Headaches
Neurol 77:1827-1832, Nagy, A.J.,et al, 2011
Headache in Transplant Patients
www.medlink.com, Aug, Lai, T.H., 2011
SMART Syndrome: A Late Reversible Complication after Radiation Therapy for Brain Tumours
J Neurol 258:1098-1104, Kerklaan, J.P.,et al, 2011
Clinical Spectrum of CADASIL and the Effect of Cardiovascular Risk Factors on Phenotype: Study in 200 Consecutively Recruited Individuals
Stroke 41:630-634, Adib-Samii,P., et al, 2010
Triptan Therapy in Migraine
NEJM 363:63-70, Loder,E., 2010
Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors
Stroke 41:2505-2511, 2455, Ducros,A.,et al, 2010
Tricyclic Antidepressants and Headaches: Systematic Review and Meta-Analysis
BMJ 341:c5222, Jackson,J.L.,et al, 2010
Migraine with Aura Triggered by Cardiac Myxoma: Case Report and Literature Review
Cephalalgia 30:1396-1399, Ceuster, L.,et al, 2010